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Abstract
Background: Many patients with cystic fibrosis develop persistent airway infection/colonization with Aspergillus fumigatus,
however the impact of A. fumigatus on clinical outcomes remains unclear. The objective of this study was to determine
whether treatment directed against Aspergillus fumigatus improves pulmonary function and clinical outcomes in patients
with cystic fibrosis (CF).
Methods: We performed a double-blind randomized placebo-controlled pilot clinical trial involving 35 patients with CF
whose sputum cultures were chronically positive for A. fumigatus. Participants were centrally randomized to receive either
oral itraconazole 5 mg/kg/d (N=18) or placebo (N=17) for 24 weeks. The primary outcome was the proportion of patients
who experienced a respiratory exacerbation requiring intravenous antibiotics over the 24 week treatment period. Secondary
outcomes included changes in FEV1 and quality of life.
Results: Over the 24 week treatment period, 4 of 18 (22%) patients randomized to itraconazole experienced a respiratory
exacerbation requiring intravenous antibiotics, compared to 5 of 16 (31%) placebo treated patients, P=0.70. FEV1 declined
by 4.62% over 24 weeks in the patients randomized to itraconazole, compared to a 0.32% improvement in the placebo
group (between group difference=24.94%, 95% CI: 215.33 to 5.45, P=0.34). Quality of life did not differ between the 2
treatment groups throughout the study. Therapeutic itraconazole blood levels were not achieved in 43% of patients
randomized to itraconazole.
Conclusion: We did not identify clinical benefit from itraconazole treatment for CF patients whose sputum was chronically
colonized with A. fumigatus. Limitations of this pilot study were its small sample size, and failure to achieve therapeutic
levels of itraconazole in many patients.
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Introduction
Aspergillus fumigatus is a common fungal organism found in the
sputum of patients with cystic fibrosis (CF) [1,2]. Evidence from
observational studies suggests that A. fumigatus is more commonly
isolated from older CF patients and from those who use chronic
maintenance therapy with inhaled antibiotics [3,4]. Whereas the
pathophysiological role of major bacteria, such as Pseudomonas
aeruginosa, is well established in CF, the relevance of fungi is poorly
understood [5,6].
National registry studies indicate that prevalence of A. fumigatus
infection is increasing in the CF population. In Canadian patients
with CF the prevalence of A. fumigatus isolated from sputum rose
from 8% in 2001 to 18% in 2009 [7,8]. As the CF population ages,
and as intensive antibiotic suppressive therapy for bacterial
infection becomes more common, the incidence and prevalence
of A. fumigatus infection is increasing.
A subgroup of CF patients who are colonized with A. fumigatus
develop allergic bronchopulmonary aspergillosis (ABPA), an
immune-mediated hypersensitivity to aspergillus that is manifested
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based on clinical criteria and evidence of a type I hypersensitivity
response against A. fumigatus [10]. However, in the absence of
ABPA, the impact of persistence of A fumigatus in the airways on
the course of CF lung disease remains unclear [11].
A retrospective cohort study from the pediatric CF clinic in
Toronto revealed that CF patients persistently infected with A.
fumigatus, who did not have ABPA, had a lower FEV1 compared to
uninfected patients, and these patients were also at a higher risk for
pulmonary exacerbations requiring hospitalization (RR=1.94,
P=0.0002) [12]. Similarly, a 3-year prospective cohort study of
adult CF patients from Canada revealed that the prevalence of
chronic infection with A. fumigatus was twice as high in patients
with frequent CF exacerbations compared to those with infrequent
exacerbations [13]. Finally, a recent case series from Israel
described a group of 6 CF patients with sputum cultures positive
for A. fumigatus who presented with respiratory deterioration that
did not respond to antibiotic treatment [14]. Treatment with the
antifungal agent itraconazole for 4–24 months resulted in
significant improvement in the patients’ clinical conditions. The
authors suggested that aspergillus-related bronchitis may be an
over-looked and largely untreated disease in CF patients [14].
The current standard of care amongst CF centers is to forego
antifungal treatment in CF patients who culture A. fumigatus in
sputum but who do not have ABPA [10]. However to date, no
prospective experimental studies have addressed the question of
whether treating aspergillus in patients with cystic fibrosis will
improve clinical outcomes. We therefore conducted a randomized,
placebo-controlled pilot clinical trial to determine if 24 weeks of
treatment with the oral antifungal agent itraconazole improved
clinical outcomes in CF patients whose sputum was chronically
colonized with A. fumigatus.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Patients
We enrolled patients with CF from 9 Canadian outpatient
centers. Patients were included in the study if they were $6 years
of age and if they had a confirmed diagnosis of cystic fibrosis made
via genetic analysis and/or sweat testing. Eligible patients had to
be chronically colonized with Aspergillus fumigatus; defined as at least
2 positive sputum cultures within the last 12 months, one of which
had to be obtained within 4 months of randomization. Patients
were excluded if they had a history of renal insufficiency (serum Cr
.1.5 times normal), significant liver disease (defined as serum
AST or ALT$2.5 times the upper limit of normal), or a history of
biliary cirrhosis or portal hypertension. Patients were also excluded
if they had active allergic bronchopulmonary aspergillosis (ABPA),
B. cepacia infection, lung transplantation, or if they had received
treatment with any antifungal agents within 6 months before
randomization. Patients were required to be clinically stable at the
time of randomization, with no antibiotic treatment for acute CF
pulmonary exacerbations allowed for at least 14 days prior to
randomization.
Study Design
The study was a double-blind, randomized, placebo-controlled,
multi-centre, pilot clinical trial incorporating two parallel treat-
ment arms. Patients underwent study assessments at baseline, and
at 4, 12, 24, and 48 weeks after randomization.
Ethics
The Research Ethics Boards of all of the participating hospitals
approved the study; project approval numbers from each Research
Ethics Board are listed in brackets: The Ottawa Hospital (2006-
768), The Hospital for Sick Children’s Hospital (1000011289), St.
Michael’s Hospital (07-242), Conjoint Health (E-21687), Hamilton
Health Sciences (08-216), University of British Columbia Provi-
dence Healthcare (H08-0204), Centre Hospitalier de L’Universite
de Montreal (08-190), The University of Western Ontario
Hospitals (15843), Queen’s University Health Sciences and
Affiliated Hospitals (DMED-1178-08), and Capital Health Hospi-
tals (CHDA-RS-2009-283). All patients (and their parents when
applicable) signed informed consent prior to study entry.
Study intervention
Patients were randomly allocated to either daily oral itracon-
azole capsules or identical placebo capsules for a 24 week
treatment period. Dosing of itraconazole was calculated to provide
a daily dose of 5 mg/kg/d as per CF Consensus Guidelines [11].
Itraconazole, or identical placebo, was given once daily by mouth,
unless the dose exceeded 200 mg/day, in which case it was given
twice daily. Patients were advised to take study medication with
orange juice or at least 8 oz of a cola beverage in order to
maximize oral absorption. Patients were also instructed to take the
study medication at least 4 hours before using medications which
decrease stomach acidity, such as histamine-blockers or proton
pump inhibitors. All study patients otherwise continued standard
therapy for their CF as prescribed by their treating physician.
Randomization
A central allocation schedule for randomisation was prepared
through a computer-generated random listing of the two treatment
allocations in variable blocks of two or four. Study medication was
dispensed by the site research pharmacist according to the
patient’s randomization assignment. Research staff and medical
staff were unaware of the treatment assignment before or after
randomization.
Outcome measures
The primary endpoint for this study was the proportion of
patients who experienced a respiratory exacerbation requiring
intravenous antibiotics over the 24 week trial treatment period.
The original intention was to extend the pilot into a larger
definitive study of 328 patients; such a study would have been
adequately powered to assess exacerbation rates as the primary
outcome. Extension of the pilot study into the larger definitive
study was dependent on demonstration of feasibility of recruit-
ment, and was dependent on additional funding being obtained
for the larger, definitive study. Neither of the latter two conditions
was met, and the pilot study was therefore not extended.
Secondary outcomes included the percentage change in FEV1
from baseline over the 24 week treatment period, as well as time to
first exacerbation and the number of exacerbations requiring
intravenous or oral antibiotics/patient-year. Changes in disease-
specific health-related quality of life over the 24 week study
treatment were assessed by the Cystic Fibrosis Questionnaire
(CFQ-R)- a disease-specific instrument that measures health-
related quality of life for children, adolescents and for adults with
cystic fibrosis [15]. CFQ-R scores were standardized on a 0 to 100
point scale with higher scores representing better quality of life.
Incidence of adverse effects and serious adverse events were also
assessed. All efficacy and safety outcomes listed were assessed at 24
weeks, but also at 48 weeks after randomization, to determine if
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weeks of therapy with itraconazole.
Statistical analysis
This was a pilot study to determine feasibility of a larger clinical
trial, and a convenience sample size of 60 was selected for the pilot
phase. Recruited patients were followed for 48 weeks.
Changes in FEV1 from baseline to week 24, and to week 48,
were compared in the 2 treatment groups using Student’s t-test.
We also compared change in FEV1 using linear regression analysis
adjusting for patient age, gender and baseline FEV1 % predicted.
The proportion of patients in the 2 groups who experienced
respiratory exacerbations was analyzed using Chi-square tests.
Kaplan Meir survival curves were used to compare time from
randomization to first exacerbation for the 2 groups. Cox
proportional hazards models were also used to adjust for patient
age, gender and baseline FEV1% predicted. The mean number of
exacerbation per patient-week was calculated using a weighted
approach to account for each patient’s duration of follow-up in the
trial. A rate ratio was produced to compare the number of
exacerbations/pt-week in the 2 groups. The 95% CI of the rate
ratio was obtained using a time-weighted Poisson regression
analysis with an incorporated overdispersion parameter using the
SAS GENMOD procedure. All analyses were intention to treat
and were conducted using SAS software, version 9.0 (SAS
Institute, Inc., Cary, North Carolina).
Results
Study Population
Patients were randomized from January 2008 to May 2010. A
total of 75 potentially eligible patients were screened for the study
however 32 patients declined to participate and 8 were ineligible
for other reasons. Recruitment into the study proved to be more
difficult than expected, and ultimately the pilot study was halted
after 35 patients had been recruited.
Thirty-five patients from 9 Canadian CF clinics were random-
ized to either receive itraconazole (n=18) or to receive placebo
(n=17) (Figure 1). One patient randomized to itraconazole
developed a rash and had to discontinue the study medication
after 7 days, a second patient developed hyperglycemia and
discontinued study medications after 152 days. Both patients
stayed in the study. One patient in the placebo group stopped
study medications prematurely at 156 days but stayed in the study.
Figure 1. Trial Profile.
doi:10.1371/journal.pone.0036077.g001
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and was lost to follow-up after randomization. No clinical outcome
data were available for this patient.
The baseline demographics and clinical characteristics of the
two groups are provided in Table 1. No significant differences
were observed for any of the baseline clinical characteristics.
Baseline serum eosinophil counts, total IgE levels and IgE RAST
levels against A. fumigatus were not significantly different between
the two groups.
Primary outcome
The primary outcome was the proportion of patients who
experienced a respiratory exacerbation requiring intravenous anti-
biotics over the 24 week treatment period (Table 2). Over the 24 week
treatment period, 4 of 18 (22%) patients randomized to itraconazole
experienced a respiratory exacerbation requiring intravenous anti-
biotics, compared to 5 of 16 (31%) placebo treated patients, P=0.70.
Secondary outcomes
The time to first exacerbation requiring oral or intravenous
antibiotics was not significantly different between groups (median
time to first exacerbation=77 days for the itraconazole group and
134 days for the placebo group, log-rank P=0.35) (Figure 2).
Adjustment of the time to first exacerbation for age, gender and
baseline FEV1 did not change the results (hazard ratio=1.34; 95%
CI: 0.57–3.14, P=0.50).
Over the 24 week treatment period 12 of 18 patients (67%)
randomized to itraconazole experienced at least one pulmonary
exacerbation requiring intravenous or oral antibiotics, compared
to 7 of 16 (44%) evaluable patients randomized to placebo
(P=0.18) (Table 2). Patients in the itraconazole-treated group and
the placebo-treated groups experienced a mean of 1.87 exacer-
bations/patient-year (0.036 exacerbations/patient-week) and 1.59
exacerbations/patient-year (0.031 exacerbations/patient-week)
respectively requiring oral or IV antibiotics, rate ratio=1.18
Table 1. Baseline Characteristics of the Randomized Patients.
Placebo (N=17) Itraconazole (N=18)
Mean Age (SD) 25.2 (9.1) 25.3 (10.5)
Male (%) 9 (53%) 10 (56%)
BMI (kg/m
2) (SD) 21.4 (4.2) 21.1 (3.1)
FEV1 (L) (SD) 2.31 (0.90) 2.09 (0.75)
FEV1% predicted (SD) 64.9% (22.2) 63.4% (18.1)
FVC% predicted (SD) 82.9% (17.4) 80.8% (17.9)
Serum eosinophils (10
9/L) (SD) 0.15 (0.11) 0.17 (0.14)
Serum IgE level (ug/L) (SD) 159 (303) 247 (335)
Serum IgE specific RAST against A. fumigatus (KU/L) (SD) 1.18 (2.81) 1.69 (4.05)
Comorbidities:
Diabetes 3 (18%) 5 (28%)
Pancreatic insufficiency 14 (82%) 16 (89%)
Coinfections:
S. aureus 8 (47%) 7 (39%)
P. aeruginosa 10 (59%) 7 (39%)
S. maltophilia 2 (12%) 7 (39%)
Medications:
Azithromycin 7 (41%) 10 (56%)
Inhaled tobramycin 12 (71%) 10 (56%)
Dornase alpha 8 (47%) 4 (22%)
Inhaled hypertonic saline 6 (35%) 4 (22%)
Inhaled corticosteroids 12 (71%) 12 (67%)
doi:10.1371/journal.pone.0036077.t001
Table 2. Pulmonary Exacerbations and Hospitalizations by Treatment Group - 24 Week Treatment Period.
24-Week Treatment Period Placebo (N=16) Itraconazole (N=18) P- value
Exacerbations requiring intravenous antibiotics 5 (31%) 4 (22%) 0.70
Exacerbations requiring oral or intravenous antibiotics 7 (44%) 12 (67%) 0.18
Hospitalizations 3 (19%) 3 (17%) 0.99
Pulmonary exacerbations/patient-year 1.59 1.87 Rate Ratio=1.18 (95% CI 0.55–2.52)
P=0.68
doi:10.1371/journal.pone.0036077.t002
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significant changes in exacerbation rates or hospitalizations
between the two groups when assessed over the 48 week follow-
up period (Table 3).
FEV1 declined by 4.62% over 24 weeks in the patients ran-
domized to itraconazole, compared to a 0.32% improvement in
FEV1 in the placebo group (between group difference=24.94%,
95% CI: 215.33 to 5.45, P=0.34). Adjustment for age, gender,
and baseline FEV1% predicted did not change the result, the
adjusted between group difference was 24.85%, P=0.34.
Similarly there was no difference in the change in FEV1 over
the entire 48 week study period (between group difference=
3.71%, 95% CI: 213.26 to 20.68, P=0.66) (Figure 3).
FVC declined by 1.95% over 24 weeks in the patients
randomized to itraconazole, compared to a 1.98% improvement
in FVC in the placebo group (between group difference=
23.93%, 95% CI: 214.65 to 6.78, P=0. 46).
Changes in quality of life were not significantly different in the 2
groups for any of the 12 domains of the CFQ-R. The respiratory
domain of the CFQ-R increased by 3.76 points (SD=10.06) for
the itraconazole group and 4.77 points (SD=24.29) for the
placebo group over the 24 week treatment period, the between
group difference was 1.01 points, P=0.87.
Adverse Effects
Nine of 18 patients randomized to itraconazole reported adverse
events compared to 5 of 17 patients in the placebo group (Table 4).
Figure 2: Time to First Pulmonary Exacerbation Requiring Oral or Intravenous Antibiotics. Blue dashed line= placebo-treated patients.
Black solid line = itraconazole-treated patients. The median time to first exacerbation was 77 days for the itraconazole group and 134 days for the
placebo group, log-rank P = 0.35. Hash marks = censored observations.
doi:10.1371/journal.pone.0036077.g002
Table 3. Pulmonary Exacerbations and Hospitalizations by Treatment Group - 48 Week Observation Period.
48-Week Observation Period Placebo (N=16) Itraconazole (N=18) P- value
Exacerbations requiring intravenous antibiotics 5 (31%) 7 (39%) 0.64
Exacerbations requiring oral or intravenous antibiotics 11 (69%) 15 (83%) 0.43
Hospitalizations 3 (19%) 4 (22%) 0.99
Pulmonary exacerbations/patient-year 1.78 2.05 Rate Ratio=1.15 (95% CI 0.64–2.30)
P=0.55
doi:10.1371/journal.pone.0036077.t003
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group, a spontaneous pneumothorax that required hospital admis-
sion. There were no episodes of hepatitis or elevations in liver
enzymes.
Plasma Levels of Itraconazole and its Metabolite
Blood was taken from participants 3 and 6 months after
randomization to assess plasma levels of itraconazole and its
metabolite hydroxy-itraconazole. Plasma was frozen and assays
were performed after the trial was completed and the random-
ization code was broken. Fourteen of 18 patients randomized to
itraconazole had plasma assays performed. In six of fourteen
patients the measured plasma levels of itraconazole and hydro-
xyitraconazole were below therapeutic levels of 300 ng/mL, the
other 8 patients had levels within the therapeutic range.
Discussion
This is the first prospective randomized controlled clinical trial
to explore whether treatment of chronic A. fumigatus airway
infection in patients with cystic fibrosis provides clinical benefits.
In this study there was no evidence of effect of 6 months of
itraconazole treatment in patients with CF who were chronically
infected with A. fumigatus. Neither lung function, exacerbation
rates, nor quality of life differed significantly between the 2
treatment groups after 24 weeks of treatment, nor after a full 48
weeks of observation.
Our original intent was to extend the pilot study into a definitive
trial of 328 randomized patients. Unfortunately recruitment into
the pilot phase was poor, and the pilot study was not extended into
a larger trial. Our study had a relatively high level of patient non-
participation (32 of 75 patients assessed for eligibility declined to
participate) which may potentially limit the representativeness of
our study sample.
Definitive conclusions cannot be drawn from our pilot trial,
since the current study is limited by a relative lack of power to
show a difference between the 2 treatment groups. However, there
was no suggestion of efficacy; patients treated with itraconazole
tended to have lower lung function, and tended to have more total
exacerbations than those treated with placebo over the 24 week
treatment period. Therefore, our pilot study did not show any
‘proof of concept’ results which would support undertaking a
larger definitive clinical trial.
There are several explanations, other than lack of statistical
power, which can potentially explain why itraconazole did not
appear to be clinically effective. The first explanation may be that
A. fumigatus, although often isolated from the sputum of patients
with CF, may not play a pathogenic role in CF patients who do
not have allergic bronchopulmonary aspergillosis. If A. fumigatus is
simply a colonizer of the CF airway, rather than an infecting
organism causing tissue injury and inflammation, then treatment
of this organism would not be expected to provide clinical benefits.
To date, studies in CF patients are inconclusive as to whether A.
fumigatus is causing infection in these patients [5,6,10], and while it
cannot be excluded that individual patients may benefit from
therapy, this current study would suggest that treatment of this
organism on the basis of sputum isolation alone is not indicated in
CF patients.
Other potential limitations of our study include eligibility
criteria which defined chronic colonization with Aspergillus fumigatus
as requiring at least 2 positive sputum cultures within the last 12
months, one of which had to be obtained within 4 months of
randomization. It is possible that patients’ infection status might
have changed within the time that elapsed between the last
positive sputum culture and randomization. A tighter definition,
requiring two positive sputum detections and a positive nucleic
acid amplification test, with the last positive culture occurring less
than 4 weeks prior to randomization, might have been preferable.
Another potential explanation for lack of efficacy may lie in the
variability of pharmacokinetics and absorption of oral itraconazole
capsules in CF patients. Although we used a dose of itraconazole of
5 mg/kg/day, which is the dose recommended in CF consensus
guidelines for treatment of allergic bronchopulmonary aspergillosis
[11], previous studies in CF patients have shown marked inter-
subject variability in absorption of oral itraconazole [16,17].
Itraconazole has the disadvantage of limited oral bioavailability,
and the capsule form requires an acidic environment for
dissolution which is inhibited by antacid therapies. Liquid forms
of itraconazole are better absorbed but are unpalatable. Studies in
CF adults have revealed that steady state concentrations are
achieved within 8 days of beginning oral itraconazole therapy, but
that only 50% of adult CF patients achieve plasma concentrations
.250 ng/mL when dosed at 2.5 mg/kg twice daily [16]. Our
study suggested similar results, 43% of patients we tested had
itraconazole plasma levels below 300 ng/mL, indicating that some
patients did not achieve therapeutic itraconazole levels, either
because of poor absorption of the drug, or because of non
adherence to the treatment protocol. Future trials in patients with
Figure 3: Changes from Baseline in FEV1 Over the 48-Week
Study. Blue dashed line= placebo-treated patients. Black solid line =
itraconazole-treated patients. 95% confidence intervals are indicated by
the error bars around the mean values.
doi:10.1371/journal.pone.0036077.g003
Table 4. Adverse Events.
Adverse Event Placebo (N=16) Itraconazole (N=18)
Spontaneous pneumothorax 0 1
Increased dyspnea 2 2
Rash 1 2
Hemoptysis 1 2
Hyperglycemia 0 1
Flu-like illness 0 3
Diarrhea 1 0
Conjunctivitis 1 0
doi:10.1371/journal.pone.0036077.t004
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measurements of serum itraconazole levels.
Aside from problems with absorption and bioavailability,
itraconazole is also a first generation azole antifungal agent.
Newer second-generation antifungal agents, such as voriconazole
and posaconazole, do exhibit a better pharmacokinetic profile, and
perhaps better potency against aspergillus species, and it is possible
that these newer agents may be more effective [18].
In summary, our pilot randomized controlled trial did not
demonstrate any clinical benefits supporting long-term itracona-
zole treatment for patients with CF whose sputum was chronically
positive for A. fumigatus. Our study was small, and relatively poor
absorption of itraconazole was observed with sub-therapeutic
plasma levels in some patients. Future larger trials, using newer
second generation azoles, with therapeutic monitoring of drug
levels, might be required to definitively determine if long-term
antifungal therapy is beneficial for these patients.
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